Abstract:BackgroundPeptide-drug-conjugates (PDCs) are being developed as an effective strategy to specifically deliver cytotoxic drugs to cancer cells. However one of the challenges to their successful application is the relatively low stability of peptides in the blood, liver and kidneys. Since AuNPs seem to have a longer plasma half-life than PDCs, one approach to overcoming this problem would be to conjugate the PDCs to gold nanoparticles (AuNPs), as these have demonstrated favorable physico-chemical and safety properties for drug delivery systems. We set out to test whether PEG coated-AuNPs could provide a suitable platform for the non-covalent loading of pre-formed PDCs and whether this modification would affect the bioavailability of the PDCs and their cytotoxicity toward target cancer cells.MethodsPeptides specifically internalized by A20 murine lymphoma cells were isolated from a phage library displaying 7mer linear peptides. Peptide specificity was validated by flow cytometry and confocal microscopy. PDCs were synthesized containing a selected peptide (P4) and either chlorambucil (Chlor), melphalan (Melph) or bendamustine (Bend). Gold nanoparticles were sequentially coated with citrate, PEG-6000 and then PDC (PDC-PEG-AuNP). The physico-chemical properties of the coated particles were analyzed by electrophoresis, TEM, UV–VIS and FTIR. Stability of free and PDC-coated AuNP was determined.ResultsBiopanning of the phage library resulted in discovery of several novel peptides that internalized into A20 cells. One of these (P4) was used to synthesize PDCs containing either Chlor, Melph or Bend. All three PDCs specifically killed A20 target cells, however they had short half-lives ranging from 10.6 to 15.4 min. When coated to PEG-AuNPs, the half-lives were extended to 21.0–22.3 h. The PDC-PEG-AuNPs retained cytotoxicity towards the target cells. Moreover, whereas pre-incubation for 24 h of free PDCs almost completely abolished their cytotoxic activity, the PDC-PEG-AuNPs were still active even after 72 h pre-incubation.ConclusionsPeptide-drug-conjugates hold potential for improving the target efficacy of chemotherapeutic drugs, however their short half-lives may limit their application. This hurdle can be overcome by easily conjugating them to gold nanoparticles. This conjugation also opens up the possibility of developing slow release formulations of targeted drug delivery systems containing PDCs.

Protein Kinase C-Delta Inhibitor Peptide Formulation Using Gold Nanoparticles

Effective delivery of a rationally designed intracellular peptide drug with gold nanoparticle-peptide hybrids.

Intracellular Delivery of Native Proteins Facilitated by Cell-Penetrating Poly(disulfide)s.

Activatable Protein Nanoparticles for Targeted Delivery of Therapeutic Peptides

Peptide-Gold Nanoparticle Hybrids as Promising Anti-Inflammatory Nanotherapeutics for Acute Lung Injury: In Vivo Efficacy, Biodistribution, and Clearance.

Conjugation with gold nanoparticles improves the stability of the KT2 peptide and maintains its anticancer properties

Peptide-Guided Nanoparticle Drug Delivery for Cardiomyocytes

Development and Characterization of Innovative Multidrug Nanoformulation for Cardiac Therapy

Highly Efficient Intracellular Protein Delivery by Cationic Polyethyleneimine-Modified Gelatin Nanoparticles

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells

Zwitterionic stealth peptide-protected gold nanoparticles enable long circulation without the accelerated blood clearance phenomenon.

Complex Coacervation-Integrated Hybrid Nanoparticles Increasing Plasmid Dna Delivery Efficiency in Vivo

Nanocarriers for Protein Delivery to the Cytosol: Assessing the Endosomal Escape of Poly(Lactide-co-Glycolide)-Poly(Ethylene Imine) Nanoparticles

Noninvasive and Efficient Peptide Delivery by a Novel Biocompatible Ionic Liquid

The Potential of Nanoscale Combinations of Self-Assembling Peptides and Amino Acids of the Src Tyrosine Kinase Inhibitor in Acute Lung Injury Therapy.

Conditional Cell-Penetrating Peptide Exposure as Selective Nanoparticle Uptake Signal

474P Evaluation of Gelatinase-Responsive Copolymeric Nanoparticles Targeting PD-1 and TGF-β Pathways for Treating Immune-Resistant Tumor

An Injectable Hydrogel Based on Phenylboronic Acid Hyperbranched Macromer Encapsulating Gold Nanorods and Astragaloside IV Nanodrug for Myocardial Infarction

Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles

Optimisation of a Microfluidic Method for the Delivery of a Small Peptide

Terminal Pegylated Dna-Gold Nanoparticle Conjugates Offering High Resistance to Nuclease Degradation and Efficient Intracellular Delivery of Dna Binding Agents